Tykerb (lapatinib; Novartis) is an orally available EGFR (epidermal growth factor receptor) and human epidermal growth factor receptor 2 (HER2) dual tyrosine kinase inhibitor. EGFR (ErbB1) and HER2 (ErbB2) form part of the ErbB family of receptor tyrosine kinases, where ligand binding ultimately results in a cascade of downstream events that regulate pathways involved in tumor growth and progression. These pathways are often amplified during tumor growth due to the overexpression of receptors and/or ligands, or because of mutation.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Tykerb : Breast cancer: HER2-positive
LIST OF FIGURES
10 Figure 1: Tykerb – SWOT analysis in HER2-positive breast cancer
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tykerb for HER2-positive
11 Figure 3: Datamonitor Healthcare drug assessment summary of Tykerb for HER2-positive
LIST OF TABLES
4 Table 1: Tykerb (lapatinib; GlaxoSmithKline) – drug profile
7 Table 2: Overview of pivotal trial data for Tykerb in HER2-positive breast cancer
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726